Organon & Co | OGN - Current Liabilities


Organon & Co reported $2.5B in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Celltrion KRW 283.62B 3.72T Dec/2025
Cspc Pharmaceutical CNY 10.18B 65.36M Dec/2025
Deva Holding AS TRY 6.43B 1.18B Sep/2023
Dianthus Therapeutics USD 38.28M 7.55M Mar/2026
Divis Laboratories Ltd INR 20.43B 3.15B Mar/2026
Gilead Sciences USD 9.48B 2.34B Mar/2026
Glaxosmithkline GBP 28.82B 144.79M Dec/2025
Kangmei Pharma CNY 5.38B 433.79M Mar/2026
Knight Therapeutics CAD 165.26M 12.58M Dec/2025
Laboratorios Farma EUR 199.84M 121.75M Dec/2023
Malin Corporation EUR 1000K 500K Dec/2024
Medical Developments International AUD 5.56M 2.26M Dec/2025
Merck USD 26.94B 1.38B Mar/2026
Neuren Pharmaceuticals AUD 4.34M 3.58M Dec/2025
Novartis USD 27.28B 4.72B Dec/2025
Organigram Holdings CAD 94.05M 32.11M Dec/2025
Organon & Co USD 2.5B 110M Mar/2026
Ovoca Bio EUR 186K 2.26M Jun/2025
Pharma Mar EUR 89.23M 4.65M Mar/2026
Qiagen NV USD 512.14M 461.26M Dec/2025
Sartorius EUR 2.11B 145.8M Mar/2026
Sino Biopharmaceutical CNY 24.85B 5.29B Jun/2025
Tilray USD 259.32M 8.32M Sep/2025
Zealand Pharma A/S 664.96M 513.61M Dec/2025